CTOs on the Move

Kala Pharmaceuticals

www.kalarx.com

 
Kala Pharmaceuticals, Inc. (Kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.kalarx.com
  • 100 Beaver St. Suite 201
    Waltham, MA USA 02453
  • Phone: 781.996.5252

Executives

Name Title Contact Details

Funding

Kala Pharmaceuticals raised $68M on 04/13/2016
Kala Pharmaceuticals raised $125M on 05/12/2021

Similar Companies

Sterling Pharma Solutions

Sterling is a CDMO or contract development and manufacturing organisation (/contract manufacturer organisation) with facilities in the UK and US.

Kowa Pharmaceuticals America

Kowa Pharmaceuticals America is a Montgomery, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PamLab

Pamlab, L.L.C. is a company focused on the future. We lead the United States with use of novel folate therapies to lower homocysteine. We are looking for hard-working, motivated and optimistic individuals who would like a challenging career and are

Marra's Pharmacy

Marra's Pharmacy is a Cohoes, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Radionetics

Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company`s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets in collaboration with Crinetics Pharmaceuticals.